BACKGROUND: Ischemia-reperfusion injury (IRI) significantly contributes to delayed graft function and inflammation, leading to graft loss. Ischemia-reperfusion injury is exacerbated by the thrombospondin-1-CD47 system through inhibition of nitric oxide signaling. We postulate that CD47 blockade and prevention of nitric oxide inhibition reduce IRI in organ transplantation. METHODS: We used a syngeneic rat renal transplantation model of IRI with bilaterally nephrectomized recipients to evaluate the effect of a CD47 monoclonal antibody (CD47mAb) on IRI. Donor kidneys were flushed with CD47mAb OX101 or an isotype-matched control immunoglobulin and stored at 4°C in University of Wisconsin solution for 6 hr before transplantation. RESULTS: CD47mAb perfusion of donor kidneys resulted in marked improvement in posttransplant survival, lower levels of serum creatinine, blood urea nitrogen, phosphorus and magnesium, and less histological evidence of injury. In contrast, control groups did not survive more than 5 days, had increased biochemical indicators of renal injury, and exhibited severe pathological injury with tubular atrophy and necrosis. Recipients of CD47mAb-treated kidneys showed decreased levels of plasma biomarkers of renal injury including Cystatin C, Osteopontin, Tissue Inhibitor of Metalloproteinases-1 (TIMP1), β2-Microglobulin, Vascular Endothelial Growth Factor A (VEGF-A), and clusterin compared to the control group. Furthermore, laser Doppler assessment showed higher renal blood flow in the CD47mAb-treated kidneys. CONCLUSION: These results provide strong evidence for the use of CD47 antibody-mediated blockade to reduce IRI and improve organ preservation for renal transplantation.
BACKGROUND:Ischemia-reperfusion injury (IRI) significantly contributes to delayed graft function and inflammation, leading to graft loss. Ischemia-reperfusion injury is exacerbated by the thrombospondin-1-CD47 system through inhibition of nitric oxide signaling. We postulate that CD47 blockade and prevention of nitric oxide inhibition reduce IRI in organ transplantation. METHODS: We used a syngeneic rat renal transplantation model of IRI with bilaterally nephrectomized recipients to evaluate the effect of a CD47 monoclonal antibody (CD47mAb) on IRI. Donor kidneys were flushed with CD47mAb OX101 or an isotype-matched control immunoglobulin and stored at 4°C in University of Wisconsin solution for 6 hr before transplantation. RESULTS: CD47mAb perfusion of donor kidneys resulted in marked improvement in posttransplant survival, lower levels of serum creatinine, blood ureanitrogen, phosphorus and magnesium, and less histological evidence of injury. In contrast, control groups did not survive more than 5 days, had increased biochemical indicators of renal injury, and exhibited severe pathological injury with tubular atrophy and necrosis. Recipients of CD47mAb-treated kidneys showed decreased levels of plasma biomarkers of renal injury including Cystatin C, Osteopontin, Tissue Inhibitor of Metalloproteinases-1 (TIMP1), β2-Microglobulin, Vascular Endothelial Growth Factor A (VEGF-A), and clusterin compared to the control group. Furthermore, laser Doppler assessment showed higher renal blood flow in the CD47mAb-treated kidneys. CONCLUSION: These results provide strong evidence for the use of CD47 antibody-mediated blockade to reduce IRI and improve organ preservation for renal transplantation.
Authors: T Suda; B N Mora; F D'Ovidio; J A Cooper; M Hiratsuka; W Zhang; T Mohanakumar; G A Patterson Journal: J Thorac Cardiovasc Surg Date: 2000-02 Impact factor: 5.209
Authors: J Levitsky; D R Salomon; M Abecassis; P Langfelder; S Horvath; J Friedewald; E Wang; S M Kurian; T Mondala; S Gil; R McDade; K Ballard; L Gallon Journal: Am J Transplant Date: 2011-07-27 Impact factor: 8.086
Authors: Jeff S Isenberg; Justin B Maxhimer; Perlita Powers; Maria Tsokos; William A Frazier; David D Roberts Journal: Surgery Date: 2008-09-02 Impact factor: 3.982
Authors: Dinna N Cruz; Sean M Bagshaw; Alan Maisel; Andrew Lewington; Ravi Thadhani; Rajasekara Chakravarthi; Patrick T Murray; Ravindra L Mehta; Lakhmir S Chawla Journal: Contrib Nephrol Date: 2013-05-13 Impact factor: 1.580
Authors: Sri G Yarlagadda; Steven G Coca; Richard N Formica; Emilio D Poggio; Chirag R Parikh Journal: Nephrol Dial Transplant Date: 2008-12-22 Impact factor: 5.992
Authors: Min Xu; Xuanchuan Wang; Babak Banan; Danielle L Chirumbole; Sandra Garcia-Aroz; Aparna Balakrishnan; Deepak K Nayak; Zhengyan Zhang; Jianluo Jia; Gundumi A Upadhya; Joseph P Gaut; Ronald Hiebsch; Pamela T Manning; Ningying Wu; Yiing Lin; William C Chapman Journal: Am J Transplant Date: 2017-12-02 Impact factor: 8.086
Authors: Zhen-Yu Xiao; Babak Banan; Jianluo Jia; Pamela T Manning; Ronald R Hiebsch; Muthukumar Gunasekaran; Gundumi A Upadhya; William A Frazier; Thalachallour Mohanakumar; Yiing Lin; William C Chapman Journal: Liver Transpl Date: 2015-01-29 Impact factor: 5.799
Authors: Xuanchuan Wang; Min Xu; Jianluo Jia; Zhengyan Zhang; Joseph P Gaut; Gundumi A Upadhya; Pamela T Manning; Yiing Lin; William C Chapman Journal: Am J Transplant Date: 2017-11-01 Impact factor: 8.086
Authors: V Švachová; L Krupičková; M Novotný; M Fialová; K Mezerová; E Čečrdlová; V Lánská; A Slavčev; O Viklický; O Viklický; I Stříž Journal: Physiol Res Date: 2021-09-10 Impact factor: 1.881
Authors: Chandu Vemuri; Gundumi A Upadhya; Batool Arif; Jianluo Jia; Yiing Lin; Joseph P Gaut; Jawad Fazal; Hua Pan; Samuel A Wickline; William C Chapman Journal: Transplant Direct Date: 2018-08-21